Skip to content

Effect of Intraoperative Salbutamol Administration on Mechanical Power and Respiratory Mechanics in Obese Patients Undergoing Laparoscopic Bariatric Surgery

Effect of Intraoperative Salbutamol Administration on Mechanical Power and Respiratory Mechanics in Obese Patients Undergoing Laparoscopic Bariatric Surgery

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07378605
Acronym
Bariatric
Enrollment
66
Registered
2026-01-30
Start date
2026-01-01
Completion date
2026-03-15
Last updated
2026-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bariatric Surgery

Brief summary

The primary objective of this study is to evaluate the effect of intraoperative salbutamol administration on mechanical power in obese patients undergoing laparoscopic bariatric surgery under general anesthesia. Mechanical power will be measured at predefined intraoperative time points (T0, T1, and T2), and changes over time will be compared to determine the impact of salbutamol on the overall energy delivered to the respiratory system during mechanical ventilation. Secondary objectives include the assessment of intraoperative respiratory mechanics, including peak airway pressure (Ppeak), plateau pressure (Pplat), driving pressure (Pdrive), airway resistance (Raw), and lung compliance, as well as gas exchange parameters (SpO₂, EtCO₂) and hemodynamic variables (mean arterial pressure). Postoperative pulmonary outcomes will be evaluated using the Melbourne Group Scale (MGS), with a score greater than 4 indicating the presence of postoperative pulmonary complications. The study aims to investigate whether improvement in intraoperative mechanical power and respiratory mechanics is associated with a reduction in postoperative pulmonary complications in this high-risk population.

Interventions

Salbutamol will be administered intraoperatively via the respiratory circuit during mechanical ventilation to assess its effect on mechanical power and respiratory mechanics.

Normal saline will be administered intraoperatively via the respiratory circuit in the same volume and manner as salbutamol to serve as a placebo

Sponsors

Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Age: 18-65 years BMI ≥35 kg/m² (candidates for obesity surgery) Scheduled for elective laparoscopic bariatric surgery ASA physical status I-III Signed informed consent

Exclusion criteria

Known allergy or contraindication to salbutamol Severe cardiovascular disease (e.g., recent MI, uncontrolled arrhythmia) Pre-existing severe pulmonary disease (e.g., severe COPD, asthma exacerbation) Pregnancy or lactation Emergency surgery Use of β-agonists or bronchodilators within 24 hours prior to surgery Patients with inability to provide informed consent \-

Design outcomes

Primary

MeasureTime frameDescription
Change in intraoperative mechanical powerBaseline (intraoperative, after establishment of pneumoperitoneum and before Ventolin or saline administration)Mechanical power will be measured directly by the ventilator/respiratory monitoring device using ventilator parameters (tidal volume, respiratory rate, peak and plateau pressures, driving pressure, and compliance) at T0, T1, and T2. The primary outcome is the difference in mechanical power between the Salbutamol and placebo groups over time.

Secondary

MeasureTime frameDescription
Peak airway pressure (Ppeak)Baseline (intraoperative, after establishment of pneumoperitoneum and before Ventolin or saline administration)Peak airway pressure will be measured directly by the ventilator/respiratory monitoring device at T0, T1, and T2 to assess intraoperative respiratory mechanics.
Plateau pressure (Pplat)Baseline (intraoperative, after establishment of pneumoperitoneum and before Ventolin or saline administration)Plateau pressure will be measured by the ventilator device at T0, T1, and T2 to evaluate changes in lung mechanics.
Driving pressure (Pdrive)Baseline (intraoperative, after establishment of pneumoperitoneum and before Ventolin or saline administration)Driving pressure (Pplat minus PEEP) will be measured via the ventilator device at all intraoperative time points to assess lung stress.
Airway resistance (Raw)Baseline (intraoperative, after establishment of pneumoperitoneum and before Ventolin or saline administration)Airway resistance will be recorded from the ventilator/monitoring device at each time point to evaluate intraoperative airway changes.
Lung complianceBaseline (intraoperative, after establishment of pneumoperitoneum and before Ventolin or saline administration)Lung compliance will be measured by the ventilator at T0, T1, and T2 to assess changes in respiratory mechanics.
Lung elastance (E)Baseline (intraoperative, after establishment of pneumoperitoneum and before Ventolin or saline administration)Lung elastance will be measured directly by the ventilator/monitoring device at each intraoperative time point (T0, T1, T2) to evaluate the stiffness of the respiratory system and its changes due to pneumoperitoneum and Ventolin/SF administration.
Heart rate (HR / Nabız)Baseline (intraoperative, after establishment of pneumoperitoneum and before Ventolin or saline administration)Heart rate will be monitored continuously and recorded at T0, T1, and T2 to evaluate intraoperative hemodynamic stability and potential effects of pneumoperitoneum and Ventolin/SF administration.
Mean arterial pressure (MAP)Baseline (intraoperative, after establishment of pneumoperitoneum and before Ventolin or saline administration)Mean arterial pressure will be monitored continuously and recorded at T0, T1, and T2 to assess intraoperative hemodynamic stability and the effects of pneumoperitoneum and Ventolin/SF administration.
Postoperative pulmonary complications (Melbourne Group Scale >4)First assessment: Within 24 hours postoperatively Second assessment: 48 hours postoperatively Third assessment: Immediately before hospital dischargeIncidence of postoperative pulmonary complications will be assessed using the Melbourne Group Scale (MGS). A score greater than 4 indicates the presence of a postoperative pulmonary complication. Criteria include: Temperature \>38°C White cell count \>11.2 ×10⁹/L or use of respiratory antibiotics Physician diagnosis of pneumonia or chest infection Chest X-ray findings of atelectasis or consolidation Production of purulent (yellow/green) sputum different from preoperative sputum Positive microbiological analysis of sputum SpO₂ \<90% in ambient air Re-admission to or prolonged stay (\>36 h) in ICU/high dependency unit for respiratory problems Patients meeting ≥4 of these criteria at any assessment point will be recorded as having a postoperative pulmonary complication.

Countries

Turkey (Türkiye)

Contacts

CONTACThülya tosun söner
hulyatosunsoner@hotmail.com+905352792102

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026